Replacement Heart Valves
Survey: Heart docs say Edwards on track for solid heart valve growth | Wall Street Beat
Edwards Lifesciences (NYSE:EW) is on track for solid growth in the transcatheter aortic valve implant market, according to a survey of cardiologists conducted by Leerink Swann analysts.
St. Jude Medical wins European approval for heart valve
Medtronic treats 1st lower-risk U.S. patient in CoreValve trial | MassDevice.com On Call
Appeals court upholds $74M Edwards Lifesciences win over Medtronic
UPDATED Nov. 13, 2012, 5:30 p.m. with comment from Medtronic
UPDATED Nov. 13, 2012, 2:30 p.m. with comment from Edwards Lifesciences
CardiAQ Valve Tech raises $33M for mitral valve replacement
Transcatheter valve maker CardiAQ Valve Technologies raised $33.2 million, successfully closing an equity funding round launched late last month.
CardiAQ, a privately held device maker developing transcatheter mitral valve replacement technology, did not disclose the names of investors.
TAVI: Mixed results for Edwards’ Sapien valve in latest Partner analysis
Newly unveiled results from Edwards Lifesciences (NYSE:EW) transcatheter aortic valve studies showed mixed results for its Sapien TAVI system when compared with surgical aortic valve replacement.
Direct Flow’s next-gen inflatable TAVI looks good at 30 days
Medical device maker Direct Flow Medical unveiled 30-day results for its namesake transcatheter aortic valve implantation system, touting reduced valve leakage and procedure-related complications for the inflatable device.
In the study, which will enroll up to 100 patients, Direct Flow’s TAVI met primary mortality endpoints with zero incidents of major vascular complications and with 95% of patients experiencing mild or less paravalvular regurgitation.
TAVI: Medtronic’s next-gen Engager looks good in 1st pivotal study results
Heart valves: Three-year Sapien data buoy Edwards Lifesciences
Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results.